1-(叔丁氧基羰基)-3-(甲烷磺酰氧基)氮杂丁烷 | 141699-58-3

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 1-(叔丁氧基羰基)-3-(甲烷磺酰氧基)氮杂丁烷
• 中文别名: 1-BOC-3-(甲磺酰氧基)吖丁啶；1-BOC-3-(甲磺酰氧基)吖啶；3-甲基磺酰氧基-1-氮杂环丁烷羧酸叔丁酯；1-Boc-3-(甲磺酰氧基)吖丁啶；N-BOC-3-甲基磺酰氧基氮杂环丁烷；3-[(甲基磺酰基)氧基]氮杂环丁烷-1-羧酸叔丁基酯；1-(叔丁氧基羰基)-3-(甲烷磺酰氧基)氮杂环丁烷；3-[(甲基磺酰基)氧基]氮杂环丁烷-1-甲酸叔丁酯
• 英文名称: 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate；tert-butyl 3-(methanesulfonyloxy)azetidine-1-carboxylate；tert-butyl 3-((methylsulfonyl)oxy)azetidin-1-carboxylate；3-(methylsulfonyloxy)azetidine-1-carboxylic acid tert-butyl ester；1-Boc-3-methanesulfonyloxyazetidine；tert-butyl 3-[(methylsulfonyl)oxy]-1-azetidinecarboxylate；tert-butyl 3-methylsulfonyloxyazetidine-1-carboxylate
• CAS: 141699-58-3
• 化学式: C₉H₁₇NO₅S
• mdl: MFCD05664832
• 分子量: 251.304
• InChiKey: XXBDTKYKFFIAEY-UHFFFAOYSA-N

物化性质

• 熔点：
  69 °C
• 沸点：
  378.5±31.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险标志：
  GHS06
• 危险性描述：
  H301
• 危险性防范说明：
  P301 + P310
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(tert-Butoxycarbonyl)-3-(methanesulfonyloxy)azetidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(tert-Butoxycarbonyl)-3-(methanesulfonyloxy)azetidine
CAS number: 141699-58-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H17NO5S
Molecular weight: 251.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(叔丁氧基羰基)-3-(甲烷磺酰氧基)氮杂丁烷 在 碘 作用下， 以 二甲基亚砜 为溶剂， 生成 1-Boc-3-碘氮杂环丁烷
  参考文献：
  名称：

  抗球虫药2,3-二芳基吲哚的合成及生物活性

  摘要：

  已经合成了在吲哚5-和6-位带有胺取代基的新型2,3-二芳基吲哚，并在体外和体内试验中将其作为抗球虫药进行了评估。对几种化合物，特别是化合物27，都检测到了亚纳摩尔体外活性和广谱体内效力。

  DOI：

  10.1016/j.bmcl.2009.01.001
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 1-(叔丁氧基羰基)-3-(甲烷磺酰氧基)氮杂丁烷
  参考文献：
  名称：

  [EN] COMPOUNDS
  [FR] COMPOSÉS

  摘要：

  揭示了一种抑制LRRK2激酶活性的新化合物，以及它们的制备方法、含有它们的组合物以及它们在治疗或预防由LRRK2激酶活性特征的疾病中的应用，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。

  公开号：

  WO2017012576A1
• 作为试剂：
  描述：

  N-Boc-3-羟基氮杂环丁烷 、 三乙胺 、 甲基磺酰氯 在 ice 、 水 、 氯化钠 、 Sodium sulfate-III 、 1-(叔丁氧基羰基)-3-(甲烷磺酰氧基)氮杂丁烷 作用下， 以 1,2-二氯乙烷 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 1-(叔丁氧基羰基)-3-(甲烷磺酰氧基)氮杂丁烷
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS

  摘要：

  本发明涉及一种用于治疗各种疾病、综合症、病况和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下式子I表示：其中R1、R2、环A和G在此定义。

  公开号：

  US20140162997A1

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] TARGETING COMPOUNDS<br/>[FR] COMPOSÉS DE CIBLAGE
  申请人：ZAFGEN INC

  公开号：WO2019118612A1

  公开（公告）日：2019-06-20

  The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  该披露提供了至少部分针对肝脏、肠道和/或肾脏的化合物，以及它们在治疗肝脏、肠道和/或肾脏疾病中的用途，如非酒精性脂肪肝、酒精性脂肪肝、肝细胞癌、肝硬化和乙型肝炎；和/或慢性肾脏疾病、肾小球疾病，如IgA肾病、狼疮性肾炎或多囊肾病。这些化合物被认为对甲硫氨酰氨肽酶2具有活性。
• HTS-based discovery and optimization of novel positive allosteric modulators of the α7 nicotinic acetylcholine receptor
  作者：István Ledneczki、Anita Horváth、Pál Tapolcsányi、János Éles、Katalin Dudás Molnár、István Vágó、András Visegrády、László Kiss、Áron Szigetvári、János Kóti、Balázs Krámos、Sándor Mahó、Patrik Holm、Sándor Kolok、László Fodor、Márta Thán、Diána Kostyalik、Ottilia Balázs、Mónika Vastag、István Greiner、György Lévay、Balázs Lendvai、Zsolt Némethy

  DOI：10.1016/j.ejmech.2021.113560

  日期：2021.10

  HTS campaign of the corporate compound collection resulted in a novel, oxalic acid diamide scaffold of α7 nACh receptor positive allosteric modulators. During the hit expansion, several derivatives, such as 4, 11, 17 demonstrated not only high in vitro potency, but also in vivo efficacy in the mouse place recognition test. The advanced hit molecule 11 was further optimized by the elimination of the

  公司化合物收集的 HTS 活动产生了一种新型的 α7 nACh 受体阳性变构调节剂草酸二酰胺支架。在命中膨胀，几个衍生物，如4，11，17证明不仅高体外效力，而且在体内在小鼠地方识别测试功效。先进的命中分子11通过消除推定的诱变芳香胺结构单元而得到进一步优化，该结构单元产生了一个新的氨基甲基吲哚化合物家族。在化合物55 的情况下发现了最平衡的物理化学和药理学特征。对接研究揭示了一个亚基间结合位点是我们的化合物最可能的。55不仅在东莨菪碱诱导的健忘症（小鼠位置识别测试）中，而且在自然遗忘（大鼠新物体识别测试）中表现出良好的认知增强特征。此外，化合物55在具有高转化价值的认知范式中是活跃的，即在大鼠触摸屏视觉辨别测试中。因此，选择55作为先导化合物进行进一步优化。基于获得的有利结果，本发明的氨基甲基吲哚簇可以通过α7 nAChR的正变构调节为认知增强提供可行的方法。
• Structure–Activity Relationship in Pyrazolo[4,3-<i>c</i>]pyridines, First Inhibitors of PEX14–PEX5 Protein–Protein Interaction with Trypanocidal Activity
  作者：Maciej Dawidowski、Vishal C. Kalel、Valeria Napolitano、Roberto Fino、Kenji Schorpp、Leonidas Emmanouilidis、Dominik Lenhart、Michael Ostertag、Marcel Kaiser、Marta Kolonko、Bettina Tippler、Wolfgang Schliebs、Grzegorz Dubin、Pascal Mäser、Igor V. Tetko、Kamyar Hadian、Oliver Plettenburg、Ralf Erdmann、Michael Sattler、Grzegorz M. Popowicz

  DOI：10.1021/acs.jmedchem.9b01876

  日期：2020.1.23

  PEX14-PEX5 protein-protein interaction (PPI) is an attractive way to affect multiple metabolic pathways. Herein, we have used structure-guided computational screening and optimization to develop the first line of compounds that inhibit PEX14-PEX5 PPI. The optimization was driven by several X-ray structures, NMR binding data, and molecular dynamics simulations. Importantly, the developed compounds show

  锥虫的原生生物是导致一系列毁灭性传染病的病原体。针对锥虫的可用化学疗法的范围是有限的，并且现有疗法部分无效并且会引起严重的不良反应。PEX14-PEX5复合物的形成对于将蛋白质导入寄生虫的糖体至关重要。这种运输对寄生虫的代谢至关重要，失败会导致糖体酶的错误定位，并对寄生虫造成致命的后果。因此，抑制PEX14-PEX5蛋白-蛋白相互作用（PPI）是影响多种代谢途径的一种有吸引力的方法。在本文中，我们已使用结构指导的计算筛选和优化方法来开发抑制PEX14-PEX5 PPI的第一类化合物。优化是由几个X射线结构，NMR结合数据，和分子动力学模拟。重要的是，已开发的化合物对锥虫具有显着的细胞活性，包括人类病原体布鲁氏冈比亚锥虫和克氏锥虫寄生虫。
• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。